Table 1.
Characteristics of recruited patients (p < 0.05 is considered as significant *).
| Patients; n = | 78 |
| Age (years); mean (range) | 72.1 (39–92) |
| Gender; n = (%) | |
| Male | 46 (58.97%) |
| Female | 32 (41.03%) |
| Primary Site of Cancer; n = | |
| Bladder cancer | 1 |
| Brain cancer | 2 |
| Breast cancer | 4 * |
| Cervical cancer | 2 |
| Cholangiocarcinoma | 1 |
| Colorectal cancer | 19 * |
| Duodenal cancer | 1 |
| Endometrial cancer | 1 |
| Esophageal cancer | 4 |
| Gastric cancer | 8 |
| Hepatocellular carcinoma | 3 |
| Head and neck cancer | 3 |
| Lung cancer (non-small cell) | 14 |
| Small cell lung cancer | 2 |
| Ovarian cancer | 2 |
| Pancreatic cancer | 2 |
| Prostate cancer | 9 |
| Vaginal cancer | 1 |
| Admission Cause; n = (%) | |
| Concomitant diseases | 34 (45.59%) |
| Cancer-related symptoms | 44 (56.41%) |
| Duration (days); median (range) | 10 (0–41) |
| Outcome; n = (%) | |
| Discharge | 40 (51.28%) |
| Death | 38 (48.72%) |
| KPS score; n = | |
| 10 | 6 |
| 20 | 5 |
| 30 | 15 |
| 40 | 15 |
| 50 | 27 |
| 60 | 9 |
| 70 | 1 |
| PaP score group; n = | |
| A | 26 |
| B | 37 |
| C | 15 |
| PPS score; n = | |
| 10 | 1 |
| 20 | 7 |
| 30 | 17 |
| 40 | 16 |
| 50 | 23 |
| 60 | 11 |
| 70 | 3 |
| PPI score; n = | |
| A | 27 |
| B | 21 |
| C | 30 |
| Use of sedatives (time of study days); n = | |
| <30% | 39 |
| 30–70% | 11 |
| >70% | 28 |
| Status of using opioids; n = | |
| decreasing use | 2 |
| stable | 29 |
| increasing use | 47 |
| Use of antipyretics (time of study days); n = | |
| <30% | 60 |
| 30–70% | 14 |
| >70% | 4 |
KPS: Karnofsky Performance Status; PaP: Palliative Prognostic Score; PPS: Palliative Performance Scale; PPI: Palliative Prognostic Index.